

NDA 204629/S-034
 NDA 206073/S-031
 NDA 206111/S-031
 NDA 208658/S-017

SUPPLEMENT APPROVAL

Boehringer Ingelheim Pharmaceuticals, Inc.
 Attention: Agnieszka Abeyta, Pharm.D.
 Associate Director, Regulatory Affairs
 900 Ridgebury Road, PO Box 368
 Ridgefield, CT 06877

Dear Dr. Abeyta:

Please refer to your supplemental new drug applications (sNDAs) submitted under section 505(b) and pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Application Number	Supplement Number	Product Name	Submission and Receipt Date
NDA 204629	S-034	Jardiance (empagliflozin) tablets	September 15, 2021
NDA 206073	S-031	Glyxambi (empagliflozin and linagliptin) tablets	September 22, 2021
NDA 206111	S-031	Synjardy (empagliflozin and metformin hydrochloride) tablets	September 22, 2021
NDA 208658	S-017	Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets	September 22, 2021

These Prior Approval sNDAs provide for revisions to the Postmarketing Experience section of the Prescribing Information of Jardiance, Glyxambi, Synjardy, and Synjardy XR to include the adverse reaction constipation.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 204629/S-034
NDA 206073/S-031
NDA 206111/S-031
NDA 208658/S-017
Page 3

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael Oyewole, Regulatory Project Manager, at (301) 796-3897.

Sincerely,

{See appended electronic signature page}

Monika Houstoun, Pharm.D., M.P.H.
Deputy Director for Safety (Acting)
Division of Diabetes, Lipid Disorders, and Obesity
Office of Cardiology, Hematology,
Endocrinology, and Nephrology
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling (Prescribing Information and Medication Guide) for Jardiance, Glyxambi, Synjardy, and Synjardy XR

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MONIKA A HOUSTOUN
03/21/2022 03:25:02 PM